Intracellular enzymatic reducing systems control receptor tyrosine kinase signaling via PTP1B.

Lucia Coppo, Wenchao Zhao, Qing Cheng, Axel Tobias Scholz, Elias S J Arnér, Markus Dagnell

Abstract read

In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Endogenous Expression of HSP70 and Thioredoxin-1 During Methamphetamine-Induced Degeneration.Biomedicines · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lucia CoppoDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID 0000-0001-6902-6346

Wenchao ZhaoDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.

Qing ChengDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID 0000-0002-3170-9333

Axel Tobias ScholzDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID 0009-0003-0166-1695

Elias S J ArnérDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID 0000-0002-4807-6114

Markus DagnellDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID 0000-0002-5925-6794

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein tyrosine phosphatases (PTPs) counteract receptor tyrosine kinase (RTK) signaling. Inhibition of PTPs by oxidation can be reversed by cytosolic thioredoxin (TXN), but less is known about regulation of PTPs by glutathione (GSH)-driven glutaredoxins (GLRXs). Here, we thus assessed GLRX1, GLRX2, and/or TXN1 in regulation of CO

Indexed as

Protein Tyrosine Phosphatase, Non-Receptor Type 1Receptor Protein-Tyrosine KinasesSignal TransductionAnimalsEpidermal Growth FactorGlutaredoxinsGlutathioneHumansHydrogen PeroxideOxidation-ReductionPhosphorylationPlatelet-Derived Growth FactorThioredoxinsEpidermal Growth FactorGlutaredoxinsGlutathioneHydrogen PeroxidePlatelet-Derived Growth FactorProtein Tyrosine Phosphatase, Non-Receptor Type 1PTPN1 protein, humanReceptor Protein-Tyrosine KinasesThioredoxins

Identifiers

PMID41961928

DOI10.1126/sciadv.adv5362

PMCPMC13068064

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.